The published studies extensively cover ilaprazole as a proton pump inhibitor,focusing on its clinical efficacy for acid-related disorders (ulcers and GERD) andH. pylori eradication, detailed pharmacokinetics andpharmacodynamics, drug interaction profile, analytical methods for quantification,safety, and cost-effectiveness. This evidence concerns the gene ATP12A and gastroesophageal reflux disease.